Related posts

Soft jobs report lifts U.S. markets, TSX flatStocks flat, Bitcoin risesSanta arrives with a rally
Investor Insights

This summary was created by AI, based on 14 opinions in the last 12 months.

Experts generally have a positive outlook on Amgen Inc. (AMGN-Q), citing its strong position in the biotech space, consistent dividend growth, and potential for future earnings and revenue growth. The company's recent acquisition is seen as a positive for its future prospects, and its long-term business outlook is considered favorable.

Consensus
Positive
Valuation
Fair Value
HOLD
Amgen Inc.

Owns this instead of NVO. A much less troublesome valuation. Also has a weight-loss drug in trial. You want to be in before the good news, not after.

biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK
Amgen Inc.
(A Top Pick Apr 11/24, Up 17.8%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with AMGN has achieved its target at $319.  To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $210) to $260.  

biotechnology / pharmaceutical
BUY
Amgen Inc.

He's surprised with how strongly shares are soaring on phase 3 trial results of their obesity drug. They're a little late to the party in these drugs, but theirs you would take less often their than peers'. Also, a recent acquisition makes them double-digit revenue growers and is accretive. Loves the dividend growth too.

biotechnology / pharmaceutical
BUY
Amgen Inc.

Legacy products that continue to do well. But new products are contributing well, too. Latest acquisition adding significantly to growth profile. Reasonable multiple of 12-13x, good prospects for growth. Out of favour, along with many healthcare stocks. Good, long-term hold.

biotechnology / pharmaceutical
BUY
Amgen Inc.

Pays a 3.2% dividend and trades at a 14x forward PE.

biotechnology / pharmaceutical
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK
Amgen Inc.
Stockchase Research Editor: Michael O'Reilly

As AI begins to play a larger role in medical intervention, AMGN is well positioned to benefit.  It has increased its dividend for 11 consecutive years.  It trades at 21x earnings and supports a robust 135% ROE.  We recommend setting a stop-loss at $210, looking to achieve $319 -- upside potential of 18%.  Yield 3.2%

(Analysts’ price target is $308.33)
biotechnology / pharmaceutical
BUY
Amgen Inc.

His impression was that the Phase 1 trial did go well. Management emphasized long way to go before it would have a monetary impact. Stock did sell off when earnings released. Still likes it. Recent acquisition will be positive for future earnings and revenue growth. Not expensive. Lots in pipeline.

biotechnology / pharmaceutical
HOLD
Amgen Inc.

Drop mainly due to NVO and LLY leading the pack on weight-loss drugs. Still, AMGN has a great lineup of drugs, revenues should grow over time. Ranks well for him. More beta than a normal healthcare stock. Now at 100-day MA, almost oversold. Makes sense from an earnings growth perspective, high single digits. Fine name, he just prefers others.

biotechnology / pharmaceutical
BUY
Amgen Inc.

Down a bit on earnings report this morning, but overlook that, short-term reaction. Phase 1 weight-loss drug primed to compete with LLY's, though not yet being promoted as its next blockbuster. Much more modest multiple than LLY.

biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Jan 11/23, Up 16%)

Reasonable multiple, mid-high teens. Good growth rate, highly predictable. Has a GLP-1 candidate, good results in Phase 1 testing. 17% of revenue goes back into R&D.

biotechnology / pharmaceutical
PARTIAL BUY
Amgen Inc.

It reports Tuesday If Eli Lilly reports 9also Tuesday) good GLP numbers, he'd buy Amgen.

biotechnology / pharmaceutical
PAST TOP PICK
Amgen Inc.
(A Top Pick Aug 08/23, Up 17%)

One of those you just buy today and hold. Pretty volatile. Secular trend in healthcare. Wide moat. 30% free cashflow. Good stock.

biotechnology / pharmaceutical
BUY
Amgen Inc.
A big gainer in Q3

They bought a pharma company, luckily wasn't blocked by the FTC. Shares jumped 21% in Q3.

biotechnology / pharmaceutical
BUY
Amgen Inc.

His choice in the biotech space.

biotechnology / pharmaceutical
BUY
Amgen Inc.

He took some money out of tech and put it into healthcare, which has seen an increase lately. He just added Amgen who delieverd a terrific report. He will continue to rally in the second half this year, will outperform tech.

biotechnology / pharmaceutical
Showing 1 to 15 of 135 entries

Amgen Inc.(AMGN-Q) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 13

Neutral - Hold Signals / Votes : 2

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 15

Stockchase rating for Amgen Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Amgen Inc.(AMGN-Q) Frequently Asked Questions

What is Amgen Inc. stock symbol?

Amgen Inc. is a American stock, trading under the symbol AMGN-Q on the NASDAQ (AMGN). It is usually referred to as NASDAQ:AMGN or AMGN-Q

Is Amgen Inc. a buy or a sell?

In the last year, 15 stock analysts published opinions about AMGN-Q. 13 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Amgen Inc..

Is Amgen Inc. a good investment or a top pick?

Amgen Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Amgen Inc..

Why is Amgen Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Amgen Inc. worth watching?

15 stock analysts on Stockchase covered Amgen Inc. In the last year. It is a trending stock that is worth watching.

What is Amgen Inc. stock price?

On 2024-05-29, Amgen Inc. (AMGN-Q) stock closed at a price of $296.55.